# Technology Advisory Committee A Interests Register
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
Publication Date: 15/09/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Steve Edwards	TA Committee A Member	Direct financial	Member of the relevant ERG for this appraisal.	NA	11/12/2020	NA	It was agreed this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave for the duration of the meeting.
Dr Abdallah Al-Mohammad	TA Committee A Member	Direct financial	Received honorarium and advisory board fees from AstraZeneca and Novartis for work relating to heart failure. He also noted that his hospital received a small grant from AstraZeneca to purchase blood pressure machines to give to patients with heart failure to enable the heart failure nurses to remotely up-titrate the medication in view of the COVID-19 restrictions. None	??	06/07/2021	N/A	It was agreed that his declaration would not prevent Dr Al-Mohammad from participating in the meeting.

			of the interests relate to breast cancer.				
Dr Mark Verrill	Clinical Expert	Direct financial	Received honoraria from Eli Lilly for lecturing, advisory boards and consultancy. He has also received honoraria from Novartis, Pfizer and Daichii Sankyo for speaker fees and advisory boards, and has received funding for studies of breast cancer treatments.	NA	10/09/2020 06/07/2021	NA	It was agreed these declarations would not prevent Dr Verrill from providing expert advice to the committee.
Ms Holly Heath	Patient Expert	Indirect financial	Employed by Breast Cancer Now, who has previously received funding from Eli Lilly and Novartis. The funding is not related to policy and campaign work.	NA	05/01/2021 06/07/2021	NA	It was agreed that this declaration would not prevent Holly from providing expert advice to the committee.